Alzinova launches global Phase II trial of Alzheimer’s vaccine candidate ALZ-101

Bitget2026/09/22 14:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

GU Ventures portfolio company Alzinova began operational start-up of a global Phase II trial for Alzheimer’s vaccine candidate ALZ-101.
Planned enrollment of about 120 early Alzheimer’s patients; first participants targeted around the 2026/2027 year-end.
Alzinova launched a rights issue of about SEK 51 million to fund ALZ-101 development and execution of the Phase II program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GU Ventures AB published the original content used to generate this news brief on September 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Alzinova launches global Phase II trial of Alzheimer’s vaccine candidate ALZ-101

You may also like

Crypto prices